The Association Between Alcohol Consumption and Left Ventricular Ejection Fraction

An Observational Study on a General Population

Zhao Li, MD, PhD, Xiaofan Guo, MD, Yinglong Bai, PhD, Guozhe Sun, MD, Yufan Guan, MD, Yingxian Sun, MD, PhD, and Abraham Maria Roselle, MD, PhD

Abstract: The results of previous studies on the relation between alcohol consumption and heart failure (HF) have been inconsistent. This study aimed to evaluate the association between alcohol consumption and left ventricular ejection fraction (LVEF) in a general population.

A total of 10,824 adults were examined using a multistage cluster sampling method to select a representative sample of individuals who were at least 35 years old. The participants were asked to provide information about their alcohol consumption. Echocardiograms were obtained, and LVEF was calculated using modified Simpson’s rule.

Of the 10,824 participants included in the present study, 46.1% were males, and the mean participant age was 54 years; age ranged from 35 to 93 years. The overall prevalence of LVEF < 0.50 and LVEF < 0.40 in the studied population was 11.6% and 2.9%, respectively. The prevalence of LVEF < 0.5 and LVEF < 0.4 was higher in both the moderate and heavy drinker groups than in the nondrinker group (P < 0.05). Multivariate logistic regression analyses corrected according to the different levels of alcohol consumption showed that moderate and heavy drinkers had an ~1.3-fold and 1.2-fold higher risk of LVEF < 0.5, respectively, than nondrinkers (OR: 1.381, 95% CI: 1.115–1.711, P = 0.003 for moderate drinkers; OR: 1.246, 95% CI: 1.064–1.460, P = 0.006 for heavy drinkers). Heavy drinkers had an ~1.5-fold higher risk of decreased LVEF < 0.4 than nondrinkers (OR: 1.482, 95% CI: 1.117–1.965, P = 0.006). Moderate drinkers did not show a risk of decreased LVEF < 0.4 that was significantly higher than that of nondrinkers (OR: 1.183, 95% CI: 0.774–1.808, P = 0.437).

According to these results, we concluded that increased alcohol consumption was associated with decreased LVEF compared with no alcohol consumption in this general population.

Abbreviations: BMI = body mass index, CVD = cardiovascular disease, DBP = diastolic blood pressure, FPG = fasting plasma glucose, GFR = glomerular filtration rate, HDL-C = high-density lipoprotein cholesterol, HF = heart failure, LDL-C = low-density lipoprotein cholesterol, LVEF = left ventricular ejection fraction, SBP = systolic blood pressure, TC = total cholesterol, TG = triglyceride, WC = waist circumference.

INTRODUCTION

The effect of alcohol on the heart is a controversial issue. Some studies have reported that alcohol intake can reduce the risk of coronary heart disease, whereas other studies have reported that alcohol use is associated with increased cardiac morbidity and mortality. The results of previous studies on alcohol consumption and heart failure (HF) have also been inconsistent. The Framingham Heart Study reported that alcohol consumption is not associated with an increased risk of congestive HF, even among heavy drinkers (>15 drinks/week in men and >8 drinks/week in women). The Olmsted County Heart Function Study concluded that in a community setting, light alcohol consumption (<1 drink a day) was associated with a reduced prevalence of moderate systolic dysfunction. The British Regional Heart Study concluded that there was no evidence that light to moderate drinking is beneficial for the prevention of HF in older men without a history of MI. However, heavier drinking (≥5 drinks/day) was associated with an increased risk of HF in susceptible men with underlying myocardial ischemia.

The latest study indicates that HF has been an important cause of cardiac mortality globally, with increasing prevalence and incidence. Although left ventricular (LV) performance can be evaluated by multiple parameters, including LV dimensions, the LV mass index, regional wall motion abnormalities, diastolic dysfunction, and left ventricular ejection fraction (LVEF) are the most representative measures of LV systolic function. However, few studies have focused on the association between alcohol consumption and HF among the general population; clarifying this relationship will be useful for the management of individuals with HF from a clinical perspective. Thus, we performed this study based on a general population from rural China with the aim of examining the association between alcohol consumption and depressed LVEF.

METHODS

Study Population

This study adopted a multistage, stratified, random cluster sampling scheme. From January 2012 to August 2013, a representative sample of individuals who were at 35 years or
older was selected in order to examine the prevalence, incidence, and natural history of cardiovascular risk factors in Liaoning Province. This research was approved by the Ethics Committee of China Medical University (Shenyang, China). Procedures were performed in accordance with ethical standards. The detailed methods have been previously published.41–44 We used baseline data in this report, and only participants who had complete data sets for the variables analyzed were included, yielding a final sample size of 10,824 individuals (4989 males and 5835 females).

**Data Collection and Definitions**

Via an interview with a standardized questionnaire, the data were obtained on demographics, lifestyle, dietary habits, income, history of heart disease, and medication used over the past 2 weeks. Blood samples were obtained from all the subjects in the morning after at least 12 hours of fasting. Serum potassium and magnesium, as well as other routine blood biochemical indexes, were analyzed using an autoanalyzer (Olympus AU 540; Olympus Corp., Kobe, Japan). The detailed process have been presented elsewhere.14,44,46,47

Hypertension was defined as SBP ≥140 mm Hg, DBP ≥90 mm Hg and/or use of antihypertensive medications according to the JNC-7 report.15 And according to the World Health Organization (WHO) criteria, body mass index (BMI) values were categorized into different groups:16 normal, overweight, and obese (for normal, BMI < 25 kg/m2; for overweight, 25 ≤ BMI < 30 kg/m2; and for obese, BMI ≥ 30 kg/m2). Participants with waist circumference (WC) ≥ 88 cm for females and WC ≥ 102 cm for males were defined as abdominal obesity.17 Dyslipidemia was determined by the National Cholesterol Education Program-Third Adult Treatment Panel (ATP III) criteria.19 FPG ≥ 7 mmol/L (126 mg/dL) and/or receiving treatment for diabetes was diagnosed as diabetes mellitus according to the following WHO criteria.19 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the glomerular filtration rate (GFR) was estimated.20,21 Reduced GFR was defined as an estimated GFR (eGFR) < 60 mL/min/1.73 m2. In accordance with WHO criteria, anemia was defined as serum hemoglobin levels < 12.0 g/L (< 12.0 g/dL) for women and < 13.0 g/dL (< 13.0 g/L) for men.22 Uric acid levels > 422 μmol/L for men and > 363 μmol/L for women was defined as hyperuricemia.22

**Echocardiography Measurements**

The transthoracic echocardiogram included M-mode, 2-dimensional, and color Doppler. Detailed measurements used in this study have been previously published.41,48 According to the guideline of American Society of Echocardiography,19 left ventricular internal dimensions (LVIDs), posterior wall thickness (PWT),as well as interventricular septal thickness (IVST) were obtained.40 Left ventricular volumes were obtained from the apical 4-chamber view and the left ventricular ejection fraction (LVEF) was computed using the modified Simpson’s rule.23,24 We used thresholds of LVEF < 0.5 and LVEF < 0.4 to indicate decreased LVEF.25,26

**Alcohol Consumption Assessment**

Alcohol consumption was assessed during the interview using the questionnaire. The participants were asked to provide information regarding whether they regularly consumed alcohol, the average amount of alcohol they consumed per day, and the number of days per month that they consumed alcohol. The amount of pure alcohol consumed was calculated based on the reported frequency and amount of drinking. In China, the ethanol weight content differed among the beverages as follows: 5% in beer, 12.5% in red wine, and 45% in hard liquor. One drink was defined as an average of 15 g of ethanol.27 We used thresholds based on the definition of daily alcohol consumption from the National Institute on Alcohol Abuse and Alcoholism to categorize the participants based on their level of consumption as follows: nondrinkers (i.e., abstainers, or no alcohol consumption history), moderate drinkers (i.e., up to 1 drink/day for women and up to 2 drinks/day for men), and heavy drinkers (i.e., > 1 drink/day for women and > 2 drinks/day for men).28

**Statistical Analysis**

Descriptive statistics were calculated for all the variables; continuous variables are reported as the mean values and standard deviations, and categorical variables are reported as counts and percentages. Differences among the categories were evaluated using nonparametric tests or the χ2 test, as appropriate. Multivariate logistic regression analyses were used to identify correlates of decreased LVEF; the association strengths are expressed as odds ratios (ORs) and corresponding 95% confidence intervals (CIs). All the statistical analyses were performed using SPSS version 22.0 and P values < 0.05 were considered statistically significant.

**RESULTS**

**Basic Characteristics of the Study Population**

Of the 10,824 participants included in the present study, 46.1% were males; the mean age was 54 years and ranged from 35 to 93 years. Of all the participants, 810 (7.5%) and 1820 (7.5%) were moderate and heavy drinkers, respectively. On average, the LVEF calculated using the modified Simpson’s rule was 0.62 ± 0.10 among the included population. The overall prevalence of LVEF < 0.50 and LVEF < 0.40 in the included population was 11.6% and 2.9%, respectively. Table 1 shows the clinical characteristics and demographics of the study population according to the alcohol consumption level. The mean age of participants in the nondrinker, moderate, and heavy drinker groups was 53.75 ± 10.56, 54.20 ± 10.79, and 53.74 ± 10.30 years, respectively. No significant differences were found among the 3 groups in the demographic and laboratory variables included in the table, except in FPG. The prevalence of comorbidities, history of stroke, history of heart disease, and diabetes was significant different among the 3 groups (all P < 0.001).

**Mean Level of LVEF and Prevalence of Decreased LVEF With Different Levels of Alcohol Consumption**

As shown in Table 2, the echocardiogram results for the left ventricle in different alcohol consumption groups showed that there were no significant differences in the left ventricular internal diastolic dimensions, interventricular septal thickness, posterior wall thickness, left ventricular internal systolic dimensions, left ventricular end-diastolic volume, and left ventricular end-systolic volume among the 3 alcohol consumption groups. However, there were significant differences in the stroke volume and the minor fraction of the left ventricle among the 3 groups. The mean level of LVEF of the nondrinker, moderate, and heavy drinker groups was 0.62 ± 0.10,
TABLE 1. Baseline Characteristics of the Study Population According to Alcohol Consumption Groups (n = 10,824)

| Variables                            | No Drinking (n = 8194) | Moderate Drinking (n = 810) | Heavy Drinking (1820) | P Value |
|--------------------------------------|------------------------|----------------------------|-----------------------|---------|
| **Age (y)**                          | 53.75 ± 10.56          | 54.20 ± 10.79              | 53.74 ± 10.30         | 0.498   |
| Male gender                          | 3750 (45.8%)           | 393 (48.5%)                | 846 (46.5%)           | 0.304   |
| Female gender                        | 4444 (54.2%)           | 417 (51.5%)                | 974 (53.5%)           | 0.304   |
| Current smoking                      | 2874 (35.1%)           | 301 (37.2%)                | 640 (35.2%)           | 0.494   |
| Family income (CNY/year)             | 2.21 ± 0.64            | 2.22 ± 0.67                | 2.21 ± 0.65           | 0.895   |
| BMI (kg/m²)                          | 24.76 ± 3.63           | 24.79 ± 3.66               | 24.93 ± 3.82          | 0.196   |
| WC (cm)                              | 82.26 ± 9.77           | 82.67 ± 9.57               | 82.48 ± 9.94          | 0.384   |
| General obesity                      | 606 (7.5%)             | 55 (7.0%)                  | 158 (8.9%)            | 0.115   |
| Abdominal obesity                    | 1196 (14.6%)           | 113 (14.0%)                | 295 (16.2%)           | 0.166   |
| SBP (mm Hg)                          | 141.51 ± 23.24         | 142.40 ± 24.04             | 141.18 ± 23.17        | 0.459   |
| DBP (mm Hg)                          | 82.06 ± 11.68          | 81.88 ± 11.60              | 81.87 ± 12.00         | 0.779   |
| TC (mmol/L)                          | 5.25 ± 1.08            | 5.25 ± 1.08                | 5.18 ± 1.07           | 0.071   |
| TG (mmol/L)                          | 1.61 ± 1.41            | 1.70 ± 1.58                | 1.69 ± 1.58           | 0.050   |
| HDL-C (mmol/L)                       | 1.41 ± 0.38            | 1.41 ± 0.39                | 1.39 ± 0.36           | 0.197   |
| LDL-C (mmol/L)                       | 2.92 ± 0.82            | 2.97 ± 0.78                | 2.92 ± 0.80           | 0.224   |
| Uric acid (mmol/L)                   | 291.84 ± 84.67         | 294.30 ± 93.63             | 293.15 ± 83.05        | 0.649   |
| FPG (mmol/L)                         | 5.85 ± 1.59            | 6.07 ± 1.86                | 6.03 ± 1.63           | <0.001  |
| Hemoglobin (g/L)                     | 138.71 ± 18.70         | 138.15 ± 19.48             | 138.27 ± 19.11        | 0.533   |
| Estimated GFR (ml/min/1.73 m²)       | 92.82 ± 15.46          | 92.27 ± 14.92              | 92.94 ± 18.27         | 0.597   |
| History of heart disease*            | 133 (16.6%)            | 93 (11.7%)                 | 180 (10.1%)           | <0.001  |
| History of stroke                    | 756 (9.4%)             | 46 (5.8%)                  | 123 (6.9%)            | <0.001  |
| Dyslipidemia                         | 2922 (36.3%)           | 298 (37.8%)                | 666 (37.4%)           | 0.551   |
| Diabetes                             | 772 (9.6%)             | 98 (12.4%)                 | 234 (13.1%)           | <0.001  |
| Hypertension                         | 4033 (50.1%)           | 414 (52.5%)                | 913 (51.3%)           | 0.361   |
| Hyperuricemia                        | 790 (9.8%)             | 88 (11.2%)                 | 170 (9.5%)            | 0.429   |

Data are expressed as the mean ± SD or as n (%). BMI = body mass index, CNY = Chinese Yuan (1CNY = 0.157 USD), DBP = diastolic blood pressure, GFR = glomerular filtration rate, FPG = fasting plasma glucose, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, SBP = systolic blood pressure, TC = total cholesterol, TG = triglyceride, WC = waist circumference.

*Includes coronary heart disease, arrhythmia and heart failure.

†The p-values were determined using the chi-square test for categorical data and using a non-parametric test for continuous data.

0.61 ± 0.10, and 0.62 ± 0.11, respectively. Compared with the nondrinker group, the mean LVEF was lower in both the moderate and heavy drinker groups (P = 0.007). We used thresholds of LVEF < 0.50 and <0.40 to indicate decreased LVEF. The prevalences of LVEF < 0.50 among the nondrinker, moderate, and heavy drinker groups were 10.9%, 14.6%, and 13.1%, respectively (Figure 1). The prevalences of LVEF <0.50 were higher in both the moderate and heavy drinker groups than

TABLE 2. Left Ventricle Echocardiogram Results in Different Alcohol Consumption Groups

| Variables   | No Drinking (n = 8194) | Moderate Drinking (n = 810) | Heavy Drinking (n = 1820) | P Value |
|-------------|------------------------|-----------------------------|----------------------------|---------|
| IVST (mm)   | 0.88 ± 0.28            | 0.89 ± 0.15                 | 0.89 ± 0.21                | 0.519   |
| LVDD (mm)   | 4.72 ± 0.43            | 4.70 ± 0.42                 | 4.69 ± 0.42                | 0.053   |
| LVSD (mm)   | 3.11 ± 0.42            | 3.14 ± 0.45                 | 3.10 ± 0.45                | 0.061   |
| PWT (mm)    | 0.87 ± 0.29            | 0.86 ± 0.10                 | 0.87 ± 0.21                | 0.808   |
| EDV (mL)    | 104.51 ± 23.24         | 103.63 ± 21.80              | 103.16 ± 22.13             | 0.057   |
| ESV (mL)    | 39.42 ± 13.38          | 40.52 ± 14.63               | 39.25 ± 14.15              | 0.068   |
| SV (mL)     | 65.09 ± 18.71          | 63.11 ± 16.44               | 63.90 ± 17.75              | 0.001   |
| LVEF        | 0.62 ± 0.10            | 0.61 ± 0.10                 | 0.62 ± 0.11                | 0.007   |
| FS          | 0.34 ± 0.07            | 0.33 ± 0.07                 | 0.34 ± 0.08                | 0.006   |

EDV = left ventricular end-diastolic volume, EF = left ventricular ejection fraction, ESV = left ventricular end-systolic volume, FS = minor fraction of the left ventricle, IVST = interventricular septal thickness, LVDD = left ventricular internal diastolic dimensions, LVSD = left ventricular internal systolic dimensions, PWT = posterior wall thickness, SV = stroke volume.
in the nondrinker group \((P = 0.001)\), and the prevalences of \(LVEF < 0.40\) among the nondrinker, moderate, and heavy drinker groups were 2.7%, 3.2%, and 3.8%, respectively (Figure 2). The prevalence of \(LVEF < 0.40\) was higher in both the moderate and heavy drinker groups than in the nondrinker group \((P = 0.021)\).

**Association Between Alcohol Consumption and LVEF**

Table 3 presents multivariate logistic regression analyses of the risk of decreased \(LVEF\) corrected according to the different levels of alcohol consumption. The analyses fully adjusted for the following factors: gender, age, height, abdominal obesity, race, education, diabetes, income, current smoking, activity level, decreased GFR, history of stroke, anemia, hyperuricemia, dyslipidemia, heart rate, history of heart disease, intake of medication over the past 2 weeks, diet score, and general obesity. After these adjustments, the data showed that the moderate and heavy drinkers had an \(\sim 1.3\)-fold and \(1.2\)-fold higher risk of \(LVEF < 0.5\), respectively, than nondrinkers \((OR: 1.381, 95\% CI: 1.115–1.711, P = 0.003)\) for moderate drinkers; \((OR: 1.246, 95\% CI: 1.064–1.460, P = 0.006)\) for heavy drinkers, and heavy drinkers had an \(\sim 1.5\)-fold higher risk of decreased \(LVEF < 0.4\) than nondrinkers \((OR: 1.482, 95\% CI: 1.117–1.965, P = 0.006)\). Moderate drinkers did not show a significantly higher risk of decreased \(LVEF < 0.4\) compared with nondrinkers \((OR: 1.183, 95\% CI: 0.774–1.808, P = 0.437)\).

**DISCUSSION**

In the present study, we first evaluated the association between alcohol consumption and \(LVEF\) in a large Chinese population. We found that both moderate and heavy drinkers were at greater risk for \(LVEF\) than were nondrinkers. This is the first study to focus specifically on the relationship between alcohol consumption and \(LVEF\) in a general population in China.

Few studies have focused on the association between alcohol consumption and left ventricular ejection fraction in the general population. In a community-based, elderly population \((76 \pm 5\, \text{years and } 60\%\, \text{women})\), higher alcohol intake was shown to be associated with lower left ventricular ejection fraction.\(^{27}\) In a population-based random sample of 2,042 adults \((\text{aged } \geq 45\, \text{years})\), a U-shaped relationship between alcohol consumption volume and \(LVEF\) was reported, and the lowest risk of moderate LV dysfunction \((LVEF \leq 40\%)\) was observed in light drinkers \((< 1 \text{ drink a day}); \text{however, no significant association was found between alcohol consumption and LV dysfunction (LVEF } \leq 5\%)^{28}\). In the present study, both moderate and heavy alcohol consumption were associated with \(LVEF < 0.5\). Heavy alcohol consumption was associated with both \(LVEF < 0.5\) and \(LVEF < 0.4\). The differences in the conclusions drawn among these studies may be due to differences in population characteristics. The present study is the first to utilize data from a rural population in China.

Based on these results, the idea that moderate alcohol consumption \((\leq 1 \text{ drink a day for women and elderly and } 1–2 \text{ drinks a day for men})\) is reasonable should be reconsidered.\(^{29}\) Moreover, \(LVEF\) is an important indicator of left ventricular systolic cardiac dysfunction.\(^{30}\) Our results suggest that individuals with HF should not consume moderate or excessive amounts of alcohol. However, long-term follow-up studies are needed to support this conclusion.

The mechanism of action of alcohol on the heart involves both ethanol and its metabolites, which induce reactive oxygen species generation, lipid peroxidation, inflammatory cytokine expression, organellar damage, and stress, as well as activate both the apoptotic and necrotic cell death pathways.\(^{31–33}\) For population-based studies, genetic and environmental factors should be considered. Studies have shown that the common homozygote of \(\text{CHRM2 rs1824024}\) is significantly associated with alcohol dependence severity.\(^{34–36}\) Moreover, the echocardiogram results indicated that further studies on the relation between alcohol use and contractility of the myocardium should also be conducted.

Our study had some limitations. We analyzed the average daily alcohol consumption, but cumulative alcohol consumption was not analyzed in this study. This information will be included in the follow-up study, and the effect of cumulative alcohol consumption on \(LVEF\) could be different from the
observations of this study. In addition, we did not statistically analyze whether the type of alcoholic drink consumed influenced LVEF. Several previous studies have suggested that wine intake had a relatively lower effect on cardiovascular disease. However, as shown in the supplementary table, nearly no wine consumption occurred within the studied population. This difference may be due to local customs and does not affect our results. In addition, our results were obtained using a cross-sectional design; thus, no cause-and-effect relationships could be established.

In conclusion, based on this general population from China, we found that increased alcohol consumption was associated with decreased LVEF compared with that of nondrinking individuals, and we recommend that the general population should consider refraining from drinking alcohol.

**REFERENCES**

1. Jelinek MV, Santamaria JD, Best JD, et al. Reversing social disadvantage in secondary prevention of coronary heart disease. *Int J Cardiol.* 2014;171:346–350.

2. Lima MC, Kerr-Córea F, Rehm J. Alcohol consumption pattern and coronary heart disease risk in metropolitan São Paulo: analyses of GENACIS Project. *Rev Bras Epidemiol.* 2013;16:49–57.

3. Almeida OP, McCaul K, Hankey GJ, et al. Excessive alcohol consumption increases mortality in later life: a genetic analysis of the health in men cohort study. *Addict Biol.* 2015;1:1–11.

4. Bobak M, Malyutina S, Horvat P, et al. Alcohol, drinking pattern and all-cause, cardiovascular and alcohol-related mortality in Eastern Europe. *Eur J Epidemiol.* 2015;31:21–30.

5. Schuckit MA. Alcohol-use disorders. *Lancet.* 2009;373:492–501.

6. Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. *Ann Intern Med.* 2002;136:181–191.

7. Aguilar D, Skali H, Moyé LA, et al. Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction. *J Am Coll Cardiol.* 2004;43:2015–2021.

8. Wannamethee SG, Whincup PH, Lennon L, et al. Alcohol consumption and risk of incident heart failure in older men: a prospective cohort study. *Open Heart.* 2015;2:e000266.

9. Farmakis D, Stafylas P, Giamouzis G, et al. The medical and socioeconomic burden of heart failure: a comparative delineation with cancer. *Int J Cardiol.* 2015;203:279–281.

10. Bøhm M, Tschope C, Wirtz JH, et al. Treatment of heart failure in real-world clinical practice: findings from the REFLECT-HF registry in patients with NYHA class II symptoms and a reduced ejection fraction. *Clin Cardiol.* 2015;38:200–207.

11. Maisin P, Desameriq G, Hemery F, et al. Relationship between recommended chronic heart failure treatments and mortality over 8 years in real-world conditions: a pharmacoepidemiological study. *Eur J Clin Pharmacol.* 2013;69:901–908.

12. Sengupta PP, Korinek J, Belohlavek M, et al. Left ventricular structure and function: basic science for cardiac imaging. *J Am Coll Cardiol.* 2006;48:1988–2001.

---

**TABLE 3. Multivariate Logistic Regression Analyses for the Association Between Increased Alcohol Consumption and Decreased Left Ventricular Ejection Fraction**

| Variables                  | LVEF<0.50 | LVEF<0.40 |
|----------------------------|-----------|-----------|
|                            | OR    | 95% CI   | P Value | OR    | 95% CI   | P Value |
| Alcohol consumption        |        |          |         |        |          |         |
| No drinking                | 1.000  | 1.000    | 0.001   | 1.000  | 1.000    | 0.023   |
| Moderate drinking          | 1.381  | 1.115–1.711 | 0.003 | 1.183  | 0.774–1.808 | 0.437 |
| Heavy drinking             | 1.246  | 1.064–1.460 | 0.006 | 1.482  | 1.117–1.965 | 0.006   |
| Female gender              | 0.763  | 0.657–0.886 | 0.000 | 0.677  | 0.510–0.900 | 0.007   |
| Age (y)                    | 1.002  | 0.995–1.009 | 0.596 | 1.011  | 0.998–1.024 | 0.096   |
| Race                       | 1.237  | 0.952–1.606 | 0.111 | 1.572  | 1.004–2.461 | 0.048   |
| Education                  | 1.001  | 0.905–1.107 | 0.984 | 0.955  | 0.790–1.155 | 0.635   |
| Family income              | 1.259  | 1.138–1.392 | 0.000 | 1.435  | 1.184–1.740 | 0.000   |
| Current smoking            | 1.010  | 0.878–1.163 | 0.887 | 1.015  | 0.779–1.323 | 0.912   |
| Physical activity          | 0.826  | 0.735–0.929 | 0.001 | 0.729  | 0.584–0.909 | 0.005   |
| General obesity            | 1.107  | 0.856–1.430 | 0.439 | 0.996  | 0.612–1.621 | 0.987   |
| Abdominal obesity          | 0.972  | 0.786–1.202 | 0.793 | 1.132  | 0.763–1.681 | 0.537   |
| Hypertension               | 1.332  | 1.164–1.523 | 0.000 | 1.304  | 1.010–1.683 | 0.042   |
| Diabetes                   | 0.911  | 0.742–1.118 | 0.371 | 0.954  | 0.654–1.390 | 0.805   |
| Decreased estimated GFR    | 1.109  | 0.721–1.707 | 0.637 | 0.660  | 0.261–1.671 | 0.381   |
| History of stroke          | 0.916  | 0.741–1.133 | 0.420 | 1.294  | 0.836–2.001 | 0.248   |
| Anemia                     | 1.042  | 0.863–1.259 | 0.668 | 1.286  | 0.921–1.796 | 0.140   |
| Hyperuricemia              | 0.732  | 0.585–0.915 | 0.006 | 0.715  | 0.462–1.107 | 0.132   |
| Dyslipidemia               | 1.049  | 0.921–1.195 | 0.470 | 1.073  | 0.840–1.371 | 0.574   |
| Heart rate                 | 1.005  | 1.001–1.010 | 0.029 | 1.005  | 0.996–1.014 | 0.281   |
| Medication used            | 1.123  | 0.993–1.270 | 0.064 | 1.171  | 0.927–1.479 | 0.184   |
| Diet score                 | 1.105  | 1.044–1.170 | 0.001 | 1.100  | 0.901–1.117 | 0.950   |
| History of heart disease   | 1.072  | 0.902–1.274 | 0.432 | 1.070  | 0.775–1.477 | 0.681   |

95% CI = 95% confidence interval, GFR = glomerular filtration rate, LVEF = left ventricular ejection fraction, OR = odds ratio.

*Indicates any self-reported medication used in the past 2 weeks.

†Includes coronary heart disease, arrhythmia, and heart failure.
13. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002;288:1252–1259.

14. Sun Z, Zheng L, Zhang X, et al. Ethnic differences in the incidence of hypertension among rural Chinese adults: results from Liaoning province. PloS One. 2014;9:e86867.

15. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–2572.

16. World Health Organization. Hypertension control: report of a WHO Expert Committee. World Health Organization technical report series. 1996;862:1–883.

17. Nishida C, Uauy R, Kumanysi K, et al. The joint WHO/FAO expert consultation on diet, nutrition and the prevention of chronic diseases: process, product and policy implications. Public health nutrition. 2004;7:245–250.

18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2489.

19. World Health Organization (WHO). Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization. 2006:1–41.

20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.

21. World Health Organization. Worldwide Prevalence of Anaemia 1993–2005: WHO Global Database on Anaemia Geneva: World Health Organization; 2008:1–51.

22. Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379:815–822.

23. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458.

24. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367.

25. Reinstadler SJ, Baum A, Rommel KP, et al. ST-segment depression resolution predicts infarct size and reperfusion injury in ST-elevation myocardial infarction. Heart. 2010;151:1819–1825.

26. Moss TJ, Krantz MJ, Zipse MM, et al. Left ventricular systolic function following alcohol septal ablation for symptomatic hypertrophic cardiomyopathy. Am J Cardiol. 2014;113:1401–1404.

27. Gonçalves A, Jund PS, Claggett B, et al. Relationship between alcohol consumption and cardiac structure and function in the elderly: the Atherosclerosis Risk In Communities Study. Circ Cardiovasc Imaging. 2015;8(8):e002846.

28. Yousaf H, Rodeheffer RJ, Paterick TE, et al. Association between alcohol consumption and systolic ventricular function: a population-based study. Am Heart J. 2014;167:861–868.

29. Martin-Moreno JM, Harris ME, Breda J, et al. Enhanced labelling on alcoholic drinks: reviewing the evidence to guide alcohol policy. Eur J Public Health. 2013;23:1082–1087.

30. Kudo R, Yu Yi K, Kasuda S, et al. Effect of alcohol on vascular function. Nihon Arakoru Yakubutsu Igakkai Zasshi. 2015;50:123–134.

31. Godfrey J, Jeanguenin L, Castro N, et al. Chronic voluntary ethanol consumption induces favorable ceramide profiles in selectively bred alcohol-prefering (P) rats. PLoS One. 2015;10:e0139012.

32. Litwiejko-Pietrycek E, Szkudlarek M, Niemcunowicz-Janica A, et al. Histological assessment of myocardium in lethal ethanol intoxication. Kardiol Pol. 2015;73:644–649.

33. Neskovic GC, Mankad S, Oh JK. Strain imaging in echocardiography: methods and clinical applications. Int J Cardiovasc Imaging. 2009;23(Suppl 1):9–22.

34. Jung MH, Park BL, Lee BC, et al. Association of CHRM2 polymorphisms with severity of alcohol dependence. Genes Brain Behav. 2011;10:253–256.

35. Luo X, Kranzler HR, Zuo L, et al. CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-controlled association study. Hum Mol Genet. 2005;14:2421–2434.

36. Wang JC, Hinrichs AL, Stock H, et al. Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet. 2004;13:1903–1911.

37. Qiao Y, Shi R, Hou B, et al. Impact of alcohol consumption on substrate remodeling and ablation outcome of paroxysmal atrial fibrillation. J Am Heart Assoc. 2015;4:e002349.

38. US Department of Health and Human Services. The physicians’ guide to helping patients with alcohol problems. Rockville, MD: US Department of Health and Human Services, Public Health Service, National Institute of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA). 1995:3769.

39. Sahn DJ, De Maria A, Kisslo J, et al. The Committee on M-mode Standardization of the American Society of Echocardiography: recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083.

40. Schiller NB, Shah PM, Crawford M. The American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms: recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358–367.

41. Zheng L, Li J, Sun Z, et al. Relationship of blood pressure with mortality and cardiovascular events among hypertensive patients aged ≥60 years in rural areas of China: a strob-compliant study. Medicine. 2015;94:e1551.

42. Naissides M, Mamo JC, James AP, et al. The effect of chronic consumption of red wine on cardiovascular disease risk factors in postmenopausal women. Atherosclerosis. 2006;185:438–445.

43. Artero A, Artero A, Tarín JI, et al. The impact of moderate wine consumption on health. Maturitas. 2015;80:3–13.

44. Yu S, Sun Z, Zheng L, et al. Prevalence of diabetes and impaired fasting glucose in hypertensive adults in rural China: far from leveling-off. Int J Environ Res Public Health. 2015;12:14764–14779.

45. Sun GZ, Li Z, Guo L, et al. High prevalence of dyslipidemia and associated risk factors among rural Chinese adults. Lipids Health Dis. 2014;13:1.

46. Guo X, Li Z, Guo L, et al. An update on overweight and obesity in rural Northeast China: from lifestyle risk factors to cardiometabolic comorbidities. BMC Public Health. 2014;14:1.

47. Sun G, Ma M, Ye N, et al. Diabetes mellitus is an independent risk factor for atrial fibrillation in a general Chinese population. J Diabetes Invest. 2016;1:6–8.

48. Zhang N, Ye N, Chen Y, et al. The relationship between snoring and left ventricular hypertrophy of China: a cross-sectional study. BMC Cardiovasc Disord. 2016;16:1.